Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.
Herrero-Martín D, Osuna D, Ordóñez JL, Sevillano V, Martins AS, Mackintosh C, Campos M, Madoz-Gúrpide J, Otero-Motta AP, Caballero G, Amaral AT, Wai DH, Braun Y, Eisenacher M, Schaefer KL, Poremba C, de Alava E. Herrero-Martín D, et al. Among authors: ordonez jl. Br J Cancer. 2009 Jul 7;101(1):80-90. doi: 10.1038/sj.bjc.6605104. Epub 2009 Jun 2. Br J Cancer. 2009. PMID: 19491900 Free PMC article.
1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.
Mackintosh C, Ordóñez JL, García-Domínguez DJ, Sevillano V, Llombart-Bosch A, Szuhai K, Scotlandi K, Alberghini M, Sciot R, Sinnaeve F, Hogendoorn PC, Picci P, Knuutila S, Dirksen U, Debiec-Rychter M, Schaefer KL, de Álava E. Mackintosh C, et al. Among authors: ordonez jl. Oncogene. 2012 Mar 8;31(10):1287-98. doi: 10.1038/onc.2011.317. Epub 2011 Aug 8. Oncogene. 2012. PMID: 21822310
A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.
Martins AS, Ordoñez JL, García-Sánchez A, Herrero D, Sevillano V, Osuna D, Mackintosh C, Caballero G, Otero AP, Poremba C, Madoz-Gúrpide J, de Alava E. Martins AS, et al. Among authors: ordonez jl. Cancer Res. 2008 Aug 1;68(15):6260-70. doi: 10.1158/0008-5472.CAN-07-3074. Cancer Res. 2008. PMID: 18676850
Targeting sarcomas: therapeutic targets and their rational.
Ordóñez JL, Martins AS, Osuna D, Madoz-Gúrpide J, de Alava E. Ordóñez JL, et al. Semin Diagn Pathol. 2008 Nov;25(4):304-16. doi: 10.1053/j.semdp.2008.07.005. Semin Diagn Pathol. 2008. PMID: 19013896 Review.
Innovative therapies in Ewing Sarcoma.
Amaral AT, Ordóñez JL, Otero-Motta AP, García-Domínguez DJ, Sevillano MV, de Álava E. Amaral AT, et al. Among authors: ordonez jl. Adv Anat Pathol. 2014 Jan;21(1):44-62. doi: 10.1097/PAP.0000000000000003. Adv Anat Pathol. 2014. PMID: 24316910 Review.
Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
Amaral AT, Garofalo C, Frapolli R, Manara MC, Mancarella C, Uboldi S, Di Giandomenico S, Ordóñez JL, Sevillano V, Malaguarnera R, Picci P, Hassan AB, De Alava E, D'Incalci M, Scotlandi K. Amaral AT, et al. Among authors: ordonez jl. Clin Cancer Res. 2015 Mar 15;21(6):1373-82. doi: 10.1158/1078-0432.CCR-14-1688. Epub 2015 Jan 21. Clin Cancer Res. 2015. PMID: 25609059
51 results